Greenwich LifeSciences (NASDAQ:GLSI) Stock Price Down 6.7% – Time to Sell?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI)’s stock price fell 6.7% on Monday . The company traded as low as $9.54 and last traded at $9.54. 61,636 shares changed hands during trading, an increase of 74% from the average session volume of 35,474 shares. The stock had previously closed at $10.22.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Greenwich LifeSciences Price Performance

The stock has a market cap of $125.40 million, a PE ratio of -11.92 and a beta of 1.69. The stock has a 50-day simple moving average of $12.01 and a 200-day simple moving average of $12.93.

Insider Buying and Selling

In related news, CEO Snehal Patel bought 2,500 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was bought at an average price of $12.51 per share, with a total value of $31,275.00. Following the completion of the transaction, the chief executive officer now directly owns 5,552,502 shares of the company’s stock, valued at approximately $69,461,800.02. This represents a 0.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last quarter, insiders acquired 6,300 shares of company stock valued at $79,965. 51.67% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its stake in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after acquiring an additional 5,861 shares in the last quarter. Northern Trust Corp boosted its holdings in Greenwich LifeSciences by 17.3% in the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock valued at $982,000 after purchasing an additional 12,923 shares during the last quarter. State Street Corp grew its position in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after buying an additional 3,005 shares in the last quarter. Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences in the third quarter worth $253,000. Finally, Barclays PLC raised its holdings in Greenwich LifeSciences by 12.7% in the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after acquiring an additional 1,088 shares in the last quarter. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.